> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rep. Waltz Questions FDA’s Telework Policy
- URL: https://www.fdaweb.com/rep-waltz-questions-fdas-telework-policy/
- Published: 2024-02-02T12:00:00.000Z
- Updated: 2026-09-14T14:22:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156285

Congressman **Mike Waltz** (R-FL) has written FDA Commissioner **Robert Califf** asking for clarification on the agency’s “telework policies… which have minimized the operational standards for approving critical drugs and therapeutics.”

Waltz noted in his [2/1 letter](https://waltz.house.gov/news/documentsingle.aspx?DocumentID=867&ref=fdaweb.com) that it has been four years since the beginning of the pandemic and FDA has “still not fully reopened to serve the American public. This has especially harmed much-needed services from the FDA as the agency continues to restrict required in-person meetings needed to approve medical therapies for the American public. It’s past time to reopen!”

The letter also is critical of FDA’s decision to maintain a “hybrid work environment” that restricts the number of participants allowed to speak during the meetings as well as the number of participants allowed to attend in-person. Additionally, it notes that FDA’s White Oak campus has a “limited number of conference rooms available to hold these meetings as they work to upgrade the existing rooms with the technology and equipment necessary to support the hybrid meeting format.”